Full name
REALITI-N: A multinational study which has both retrospective and prospective phases to study effectiveness and improvements in Health-related Quality of Life (HRQoL) among adult participants with a confirmed diagnosis of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) over 12 months of mepolizumab use in a real-world setting.
NCT Number
GSK Identifier:218955
Geography
US
Non-US
Locations
France, Greece, Italy, Spain, United States
Primary Endpoints
Mean Change from Baseline in Sino-Nasal Outcome Test-22 (SNOT-22) at 12 months
External Link
https://www.gsk-studyregister.com/218955
Order
0
Disease
Version
Phase
4
QR code description
Scan QR Code to view the Study Summary on the GSK Study Register site
Status
Recruiting